NCCN Guidelines Insights: Malignant Pleural Mesothelioma, Version 3.2016

Restricted access

These NCCN Guidelines Insights focus on recent updates to the NCCN Guidelines for Malignant Pleural Mesothelioma (MPM). These NCCN Guidelines Insights discuss systemic therapy regimens and surgical controversies for MPM. The NCCN panel recommends cisplatin/pemetrexed (category 1) for patients with MPM. The NCCN panel also now recommends bevacizumab/cisplatin/pemetrexed as a first-line therapy option for patients with unresectable MPM who are candidates for bevacizumab. The complete version of the NCCN Guidelines for MPM, available at NCCN.org, addresses all aspects of management for MPM including diagnosis, evaluation, staging, treatment, surveillance, and therapy for recurrence and metastasis; NCCN Guidelines are intended to assist with clinical decision-making.

Provided content development and/or authorship assistance.

Supplementary Materials

    • Supplemental Material (PDF 236 KB)
All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 948 948 93
PDF Downloads 119 119 15
EPUB Downloads 0 0 0